Chief Scientific Officer, FibroBiologics
Assessing Efficacy of Fibroblast Cell Technology in MS and Directing Future Clinical Study: Hamid Khoja, PhD
Discussing data from an early safety study, the chief scientific officer of FibroBiologics commented on the benefits of a staggered approach to their clinical research in multiple sclerosis. [WATCH TIME: 5 minutes]
Takeaways for Clinicians on CYMS101 in Multiple Sclerosis: Hamid Khoja, PhD
The chief scientific officer of FibroBiologics discussed the benefits of fibroblast cell technology for this patient population, particularly the absence of adverse effects. [WATCH TIME: 3 minutes]
Fibroblasts for Treatment of Multiple Sclerosis: Hamid Khoja, PhD
The chief scientific officer of FibroBiologics spoke on fibroblast cell technology and its specific benefits in comparison stem cell therapy. [WATCH TIME: 4 minutes]